Forward Industries, Inc. - 10-Q Summary (Q2 Fiscal 2009)
Business Context and Reporting Period
Company: Forward Industries, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended March 31, 2009 (Fiscal Q2 2009).
Business Overview: The Company designs, markets, and distributes custom soft-sided carrying cases for portable electronic devices, primarily blood glucose monitoring kits for diabetics and other consumer electronics. Sales are made to Original Equipment Manufacturers (OEMs) in the Americas, Europe, and the Asia Pacific (APAC) region.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2009 |
Three Months Ended Mar 31, 2008 |
Six Months Ended Mar 31, 2009 |
Six Months Ended Mar 31, 2008 |
|---|---|---|---|---|
| Net Sales | $4,256,951 | $4,727,704 | $9,563,593 | $9,680,794 |
| Gross Profit | $663,528 | $619,060 | $1,607,531 | $1,736,880 |
| Gross Margin % | 15.6% | 13.1% | 16.8% | 17.9% |
| Operating Loss | ($712,855) | ($727,049) | ($1,110,974) | ($1,323,858) |
| Net Loss | ($1,051,218) | ($358,123) | ($1,255,642) | ($645,187) |
| Loss Per Share (Basic/Diluted) | ($0.13) | ($0.05) | ($0.16) | ($0.08) |
| Cash and Equivalents | $18,968,569 (as of Mar 31, 2009) | |||
| Working Capital | $22,306,636 (as of Mar 31, 2009) | |||
| Debt | No short or long-term debt outstanding. |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 10% in the quarter and 1% for the six-month period compared to the prior year. The decline was driven primarily by a 12% drop in diabetic product sales, specifically a $0.9 million decrease in sales to Lifescan (the largest customer), partially offset by growth from other diabetic customers.
- Net Loss Expansion: Net loss increased significantly ($0.7 million for the quarter) primarily due to a $0.5 million income tax expense resulting from the establishment of a full valuation allowance against deferred tax assets. This contrasts with an income tax benefit in the prior year period.
- Gross Profit Improvement: Despite lower sales, gross profit increased slightly in the quarter due to a $0.4 million reduction in the reserve for obsolete inventory, which offset higher material and operating costs.
- Interest Income: Other income declined 65% due to lower average interest rates on cash balances.
Guidance, Outlook, and Risks
- Economic Environment: Management cites deteriorating economic conditions, rising unemployment, and tight credit markets as adverse factors impacting consumer spending on electronic devices.
- Customer Strategy Risks: Several OEM customers have proposed changing their "in-box" business model to include lower-cost, simplified carry solutions to reduce expenses. This trend poses a material risk to future revenue and gross margins.
- Liquidity: The Company maintains strong liquidity with approximately $19 million in cash and no outstanding debt. Management anticipates current resources are adequate for the next 12 months.
- Valuation Allowance: The Company established a $511,000 valuation allowance against deferred tax assets, determining it is not "more likely than not" that these assets will be utilized, except for taxes on repatriated foreign income.
- Contractual Obligations: The Company has a non-exclusive license with Motorola that expired March 31, 2009, and was not renewed. Minimum royalty obligations were eliminated via amendment in December 2008.
Investor Verification Checklist
- Customer Concentration: Verify the extent of reliance on Lifescan and other major diabetic OEMs, given the significant sales decline to Lifescan.
- "In-Box" Model Shift: Assess the impact of OEMs moving to lower-cost accessory models on future gross margins and revenue volume.
- Deferred Tax Assets: Review the justification for the full valuation allowance and the likelihood of future profitability to utilize these assets.
- Inventory Reserves: Monitor the trend in obsolete inventory reserves, which provided a temporary boost to gross profit in this period.
- Foreign Earnings: Note the $4.0 million in undistributed foreign earnings (Swiss subsidiary) and the potential tax implications if repatriated.